Elypta awarded €2.35 million from Horizon 2020 SME instrument

Feb 4, 2019

Elypta today announced it is one of the winners in the European Union’s Horizon 2020 Research and Innovation Programme SME instrument phase 2 and has been awarded Euros 2.35 m. The grant will fund the first ever multicenter trial for diagnoses of renal cell carcinoma (RCC), aimed at validating the company's innovative metabolism-based liquid biopsy platform for early detection of recurrent RCC and thus enabling the test to be launched in Europe and the US.

Swedish press release

Select press coverage:

Nordic Life Science

Life Science Sweden


Studies mentioned

No items found.